19:09:07 EST Sun 28 Feb 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Aeterna Zentaris Inc (3)
Symbol AEZS
Shares Issued 41,054,387
Close 2020-07-30 C$ 0.64
Recent Sedar Documents

Aeterna files two patent applications for macimorelin

2020-07-31 09:15 ET - News Release

Dr. Klaus Paulini reports

AETERNA ZENTARIS ANNOUNCES CONTINUED EXPANSION OF INTELLECTUAL PROPERTY PORTFOLIO FOR MACIMORELIN WITH ADDITIONAL PATENT APPLICATIONS

Aeterna Zentaris Inc. filed two patent applications on July 22, 2020, related to its substance macimorelin, an orally available ghrelin agonist to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD) and childhood-onset growth hormone deficiency (CGHD).

Based on the positive results from AEZS-130-P01 ("Study P01") evaluating macimorelin as a growth hormone stimulation test for the evaluation of CGHD, the Company filed a U.S. provisional application as well as a patent application under PCT (Patent Cooperation Treaty). Both patent applications relate to the invention of macimorelin as a method to diagnose growth hormone deficiency in pediatric patients.

"We are encouraged with the data macimorelin has demonstrated to date and believe it holds significant potential to expand into pediatric use. These patent applications, once granted, are expected to support Aeterna's business case for its continued development and efforts to seek regulatory approval pending the outcome of our second pediatric study, P02, evaluating macimorelin acetate in pediatric patients from 2 years of age to 18 years of age with suspected growth hormone deficiency," commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna.

For results of Study P01, please visit EU Clinical Trials Register and reference EudraCT #2018-001988-23.

About Macimorelin

Macimorelin, a ghrelin agonist, is an orally-active small molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of macimorelin for the assessment of GHD. In December 2017, the United States Food and Drug Administration ("FDA") granted Aeterna Zentaris marketing approval for macimorelin to be used in the diagnosis of patients with adult growth hormone deficiency. Macrilen{&#A A ; ™} has been granted Orphan Drug designation by the FDA for diagnosis of AGHD. In January 2019, the European Commission granted marketing authorization for macimorelin to Aeterna Zentaris for diagnosis of growth hormone deficiency in adults. In March 2017, the Pediatric Committee of the EMA agreed to the Company's PIP for macimorelin, a prerequisite for filing a marketing authorization application for any new medicinal product in Europe.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen{&#A A ; ™} (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen{&#A A ; ™} is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.